Key facts
- Alpha Fusion’s last known valuation is $20.7M.
- It has raised $11.9M; the latest was Early Stage VC ($7.1M) in Oct 2024.
- Notable investors include Global Brain, SBI Investment, Osaka University Venture Capital, Toshiba (Tokyo), D3 (Tokyo) — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Alpha Fusion
- ·The full record, as it builds
Funding rounds
No funding rounds for Alpha Fusion are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Alpha Fusion
Developer of alpha nuclear medicine therapy using astatine intended to provide innovative cancer treatment. The company engaged in drug discovery and business development of low-molecular-weight and antibody-introduced astatine compounds, enabling healthcare prodessionals to give cures for cancer with alpha-ray nuclear medicine therapy.
- Sector
- Healthcare
- HQ
- Osaka, Japan
- Founded
- 2021
- Website
- alpha-fusion.com/
- Ownership
- Privately Held (backing)
Alpha Fusion doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Alpha Fusion shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Alpha Fusion in its N-PORT filings yet. We sweep new filings monthly.